Aquestive Therapeutics, Inc. Quarterly Depreciation in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Aquestive Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q1 2018 to Q2 2024.
  • Aquestive Therapeutics, Inc. Depreciation for the quarter ending June 30, 2024 was $165K, a 34% decline year-over-year.
  • Aquestive Therapeutics, Inc. Depreciation for the twelve months ending June 30, 2024 was $950K, a 33.9% decline year-over-year.
  • Aquestive Therapeutics, Inc. annual Depreciation for 2023 was $1.15M, a 49.2% decline from 2022.
  • Aquestive Therapeutics, Inc. annual Depreciation for 2022 was $2.27M, a 22% decline from 2021.
  • Aquestive Therapeutics, Inc. annual Depreciation for 2021 was $2.91M, a 14.2% decline from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $950K $165K -$85K -34% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $1.04M $168K -$118K -41.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $1.15M $399K +$55K +16% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 $1.1M $218K -$339K -60.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $1.44M $250K -$405K -61.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $1.84M $286K -$428K -59.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $2.27M $344K -$373K -52% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 $2.64M $557K -$167K -23.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $2.81M $655K -$73K -10% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $2.88M $714K -$29K -3.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $2.91M $717K -$547K -43.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $3.46M $724K +$10K +1.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $3.45M $728K +$28K +4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $3.42M $743K +$29K +4.06% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $3.39M $1.26M +$552K +77.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 $2.84M $714K +$19K +2.73% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 $2.82M $700K -$11K -1.55% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $2.83M $714K -$22K -2.99% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $2.85M $712K -$36K -4.81% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 $2.89M $695K -$38K -5.18% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $2.93M $711K -$54K -7.06% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $2.98M $736K -$204K -21.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $3.19M $748K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 $733K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $765K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $940K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.